Drug Profile
Zifanocycline - KBP Biosciences
Alternative Names: KBP-7072Latest Information Update: 04 Mar 2024
Price :
$50
*
At a glance
- Originator KBP Biosciences
- Class Antibacterials; Heterocyclic bicyclo compounds; Small molecules; Tetracyclines
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Bacterial infections
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for phase-I development in Bacterial-infections(In volunteers) in USA (PO, Capsule)
- 28 Aug 2022 No recent reports of development identified for preclinical development in Bacterial-infections in China (PO)
- 16 Aug 2022 Phase I trials in Bacterial infections (In volunteers) in USA (IV) (NCT05507463)